Micro ribonucleic acid in relation to the heterogeneous reactivity of antiplatelet drugs:progress and perspectives
Received:May 22, 2018  Revised:July 05, 2018
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2018.12.217
Key words:micro ribonucleic acid  antiplatelet drug  heterogeneity of reactivity  P2Y12 receptor antagonist
Author NameAffiliationE-mail
LIU Jun Department of Cardiology, Chinese PLA General Hospital,
National Clinical Research Center for Geriatric Diseases, Beijing 100853, China 
 
YIN Tong Department of Cardiology, Chinese PLA General Hospital,
National Clinical Research Center for Geriatric Diseases, Beijing 100853, China 
yintong2000@yahoo.com 
Hits: 1327
Download times: 1011
Abstract:
      Antiplatelet drugs play an established role in the prevention and treatment of cardiovascular and cerebrovascular events associated with atherothrombosis, but heterogeneous reactivity poses risks of serious ischemia or bleeding. Finding predictive biomar-kers of the heterogeneous reactivity of antiplatelet drugs is of great clinical value for their personalized use. Studies in recent years have found that platelets are a major source of miRNA, and much attention has been attracted to correlation between the platelet miRNA that can potentially regulate the expression of platelet P2Y12 and antiplatelet reactivity of P2Y12 receptor antagonists. This paper reviews the biological characteristic, correlation studies, and possible mechanisms of platelet microRNA in relation to reactivity of antiplatelet drugs.
Close